[Ketamine i. v. for the treatment of cluster headaches : An observational study]. / Ketamin i. v. zur Behandlung von Clusterkopfschmerz : Eine Beobachtungsstudie.

Cluster headaches have an incidence of 1-3 per 10,000 with a 2.5:1 male-to-female gender ratio. Although not life threatening, the impact of the attacks on the individual patient can result in tremendous pain and disability. The pathophysiology of the disease is unclear, but it is known that the hypothalamus, the brainstem, and genetic factors, such as the G1246A polymorphism, play a role. A distinction is made between episodic and chronic cluster headaches. In a controlled setting, we treated 29 patients with cluster headaches (13 with chronic cluster and 16 with the episodic form), who had been refractory to conventional treatments, with a low dose of ketamine (an NMDA receptor antagonist) i.v. over 40 min to one hour every 2 weeks or sooner for up to four times. It was observed that the attacks were completely aborted in 100 % of patients with episodic headaches and in 54 % of patients with chronic cluster headaches for a period of 3-18 months. We postulated neuroplastic brain repair and remodulation as possible mechanisms.

Isolation and characterization of a flocculating protein from Moringa oleifera Lam.

A flocculating protein from the seeds of Moringa oleifera Lam. was isolated by extraction with phosphate buffer followed by cation exchange chromatography. The molecular mass of the protein determined by SDS-PAGE was about 6.5 kDa, the isoelectric point was above pH 10. Amino acid analysis and sequencing showed high contents of glutamine, arginine and proline, and a total of 60 residues. The amino terminus is blocked by pyroglutamate. The flocculant capacity, determined in glass powder suspension, is comparable to that of a cationic polymer on polyacrylamide basis. Flocculation activity may be explained by the patch charge mechanism due to low molecular weight and high charge density.

[Non-opioid analgesics and co-analgesics in therapy of chronic pain]. / Nicht-Opioidanalgetika und Co-Analgetika in der Therapie chronischer Schmerzen.

Efficacy and side effects of non-opioid-analgesics were analysed in a standardized review of placebo-controlled or double-blind studies. In rheumatoid arthritis, ibuprofen showed the best ratio of effectiveness and side-effects. Naproxen, diclofenac and meloxicam may serve as alternatives. In osteoarthritis, naproxen seems to be superior to diflunisal, meloxicam and diclofenac. In cancer pain, ibuprofen is the treatment of the first choice followed by naproxen and diclofenac. No sufficient data on non-opioids in neuropathic pain were available. The dose administered in the management of chronic pain should be low in order to reduce the incidence of side-effects. The frequency of side-effect-related discontinuation of chronic pain medication was calculated as follows: ibuprofen 3.8%, aspirin 4.7%, piroxicam 4.8%, naproxen 7.4%, meloxicam 13.0% and diclofenac 17.8%. Since differences in efficacy were not clinically relevant, the indication for a special non-opioid-analgesic medication should focus on the prevention of side-effects.

[Spinal anaesthesia in day-case surgery. Optimisation of procedures]. / Spinalanästhesie in der Tageschirurgie. Optimierung der Abläufe.

BACKGROUND: Since prilocaine is being increasingly used for day case surgery as a short acting local anaesthetic for spinal anaesthesia and because of its low risk for transient neurological symptoms, we compared it to bupivacaine. PATIENTS AND METHODS: Patients (n=88) who were scheduled for lower limb surgery with spinal anaesthesia randomly received 15 mg hyperbaric bupivacaine 0.5% or 60 mg hyperbaric prilocaine 2% (administered in a sitting position). Onset time, intensity, duration of the sensomotoric block, vital parameters and time of spontaneous miction were recorded and patients were questioned on satisfaction with the anaesthesia procedure and the occurrence of adverse side-effects after 24 h. RESULTS: Bupivacaine caused a significantly higher sensory block than prilocaine (T6 vs. T8). Both groups were similar in reaching an analgesic level of at least T12, block intensity and onset times. Median analgesic levels at T12 were maintained for 60 min with prilocaine versus 120 min with bupivacaine, regression of the motor block was 135 min versus 210 min, sensory block S1 was 240 min versus 360 min, and time for spontaneous miction was 306 min versus 405 min, respectively (differences for all comparisons were statistically significant). CONCLUSION: Under the present study conditions, hyperbaric prilocaine 2% was superior to hyperbaric bupivacaine 0.5% due to a shorter effect profile but otherwise equivalent quality of block. However, puncture in a sitting position and positioning with elevated torso for restriction of the cranial expansion of block spread might cause an enhanced sacral block with delayed recovery of bladder function.

[Characteristics of the heart rate of emergency physicians in emergency helicopters]. / Herzfrequenzverhalten von Notärzten beim Einsatz im Notarzthubschrauber.

The heart rate behaviour of 14 emergency doctors was examined in 50 cases of medical emergency service by helicopter. In addition, the subjective stress experienced by the probands was inquired by means of a questionnaire. The alarm and the landing at the site of the emergency resulted in the most marked heart rate increases; also during the period of approaching the patient, his rescue and care, persistent tachycardia could be observed. Recovery began slowly during the return flight, but even 15 minutes after completion of the emergency task the heart rate was still higher than the original value before the alarm had been sounded. Subjectively the total stress was considered to be generally low in the opinion of the emergency doctors. It seems that unconscious mechanisms of repression prevent the actual realistic recording of physical and emotional stress during the emergency service by helicopter.

[Complex regional pain syndrome I and II. What effects the outcome?]. / Komplexe regionale Schmerzsyndrome CRPS I und II. Was beeinflusst den Langzeitverlauf?

INTRODUCTION: The results of clinical studies have raised doubts on the effectiveness of regional sympathetic blocks with guanethidine (IVRSB) in patients suffering from complex regional pain syndrome (CRPS). We conducted a retrospective analysis of long-term results in our patients and searched for possible factors predicting long-term outcome after IVRSB: METHODS: After approval by our ethics commission and written informed consent, 42/44 patients were included. We documented diagnosis, history, therapy and long-term result from charts. Long-term results were also obtained from a questionnaire administered to the patients. These were defined as very good (reduction of pain > or =75%), good (pain reduction <75% and > or =50%), moderate (pain reduction <50% and > or =25%) or poor (pain reduction <25%). The association of a moderate or poor outcome with the factors age, gender, duration of time until therapy, pain intensity before therapy, dose of applied guanethidine and duration of therapy was calculated by odds ratio. Confidence intervals for the odds ratios were determined by Woolfs approximation. RESULTS: After a mean duration of 18 months, the outcome was classified as very good in 14, good in 13, moderate in 5 and poor in 10 patients. An increased rate of moderate or poor outcome was associated with age<60 years (OR=4.00, CI 1.04-15.26), male gender (OR=2.93, CI 0.71-12.11) and duration of therapy>2 weeks (OR=3.27, CI 0.86-12.36). The factors duration of time until therapy, initial pain intensity and total dose of guanethidine were not associated with increased rates of moderate or poor outcome. CONCLUSION: We only seldom observed a complete functional restoration after CRPS. Male patients <60 years showed an increased risk of developing chronic pain. It remains unclear whether the risk of chronic pain reflects different responses to therapy or differences in the natural course of the disease in our patients. A meta-analysis of randomised trials of IVRSB in CRPS failed to prove the effectiveness of this intervention. If other investigations confirm our impression, future studies of CRPS-treatments should be planned and analysed with regard to the possible influence of the natural course and different risks of chronic pain among patients with CRPS.

Aggressive management of recurrent ovarian cancer--the challenge of individualizing cancer therapy illustrated by a case report.

BACKGROUND: In clinical practice, treatment recommendations and the patient's wishes often diverge, facing the physician with difficult choices. CASE REPORT: The clinical course of a 36-year-old patient with 'platinum-refractory' ovarian cancer is reported. The patient experienced a symptomatic relapse 7 months after debulking surgery and completion of platinum-based first-line chemotherapy. As she had given birth to a son 22 months before diagnosis, she fought with outmost determination against her disease. Her husband supported her, and both asked for maximal therapy, including intensive care treatment for recurrent respiratory tract infections and total parenteral nutrition (TPN). For the patient, it was of major importance to stay with her family and make sure that her son would be able to remember his mother. Problems related to TPN and progression of disease affected her individual perception of quality of life to a much lower extent than expected and perceived by her caretakers. All professional health care providers were more than once very reluctant to continue treatment and only after extensive counseling gave in to the demand of the patient for further treatment, considering the effort futile - only to be surprised by treatment response and recovery. After 3 years of palliation, the tumor was resistant to all cytotoxic regimens and the patient died 2 months after withdrawal of chemotherapy. CONCLUSION: This case report illustrates that also in the age of evidence-based medicine individualized treatment beyond proven strategies can offer patient benefit. Taking the child's development into account makes it impossible to determine the cost-benefit ratio.